BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Danvatirsen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Danvatirsen\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05986240-2288@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Danvatirsen: Phase 1 readout est. (NCT05986240)
DESCRIPTION:Danvatirsen\, phase 1.\nStudy: Danvatirsen Monotherapy Followed
  by Combination With Venetoclax in Relapsed/Refractory MDS & AML\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/danvatirsen#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05986240
URL:https://assetmemo.bio/drug/danvatirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
